PAR 0.00% 21.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-1518

  1. 326 Posts.
    lightbulb Created with Sketch. 37
    This is very interesting as we are a fair way behind as we haven't started phase 3. I don't recall this being mentioned in any of the releases from PAR as a competitor.
    I am sure Mozz will research and equip us with whatever comparatives are known. I will wait and see. OA is a huge market but first to commercialise has a significant advantage
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.